Trial Outcomes & Findings for VNS During Rehabilitation for Improved Upper Limb Motor Function After Stroke (NCT NCT02243020)

NCT ID: NCT02243020

Last Updated: 2022-09-15

Results Overview

Measurement of impairment, minimum value 0, maximum value 66, higher score means a better outcome. Subscales are summed.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

17 participants

Primary outcome timeframe

6-weeks

Results posted on

2022-09-15

Participant Flow

Recruitment was from January 2016 through August 2017 at 3 US and 1 UK sites.

Participant milestones

Participant milestones
Measure
Vagus Nerve Stimulation (VNS) + Rehabilitation (1)
This group receives vagus nerve stimulation during rehabilitation. VNS and rehabilitation are the interventions. Vagus Nerve Stimulation (VNS)
Vagus Nerve Stim (VNS) + Rehabilitation (2) - Comparator
This group receives rehabilitation and VNS, but the VNS is different than given in the other group (rehabilitation is the only true intervention in this group). It may not be as effective as the other group's settings. Both groups receive the same amount of rehabilitation. Vagus Nerve Stimulation (VNS)
Overall Study
STARTED
8
9
Overall Study
COMPLETED
8
9
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

VNS During Rehabilitation for Improved Upper Limb Motor Function After Stroke

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Vagus Nerve Stimulation (VNS) + Rehabilitation (1)
n=8 Participants
This group receives vagus nerve stimulation during rehabilitation. VNS and rehabilitation are the interventions. Vagus Nerve Stimulation (VNS)
Vagus Nerve Stim (VNS) + Rehabilitation (2) - Comparator
n=9 Participants
This group receives rehabilitation and VNS, but the VNS is different than given in the other group (rehabilitation is the only true intervention in this group). It may not be as effective as the other group's settings. Both groups receive the same amount of rehabilitation. Vagus Nerve Stimulation (VNS)
Total
n=17 Participants
Total of all reporting groups
Age, Continuous
59.5 years
STANDARD_DEVIATION 7.4 • n=39 Participants
60.0 years
STANDARD_DEVIATION 13.5 • n=41 Participants
59.8 years
STANDARD_DEVIATION 10.5 • n=35 Participants
Sex: Female, Male
Female
4 Participants
n=39 Participants
4 Participants
n=41 Participants
8 Participants
n=35 Participants
Sex: Female, Male
Male
4 Participants
n=39 Participants
5 Participants
n=41 Participants
9 Participants
n=35 Participants
Region of Enrollment
United States
4 Participants
n=39 Participants
5 Participants
n=41 Participants
9 Participants
n=35 Participants
Region of Enrollment
United Kingdom
4 Participants
n=39 Participants
4 Participants
n=41 Participants
8 Participants
n=35 Participants
Time Since Stroke
1.5 years
STANDARD_DEVIATION .7 • n=39 Participants
1.5 years
STANDARD_DEVIATION .3 • n=41 Participants
1.5 years
STANDARD_DEVIATION .5 • n=35 Participants
Baseline Upper Extremity Fugl-Meyer (UEFM)
29.5 units on a scale
STANDARD_DEVIATION 6.4 • n=39 Participants
36.4 units on a scale
STANDARD_DEVIATION 9.4 • n=41 Participants
33.2 units on a scale
STANDARD_DEVIATION 8.0 • n=35 Participants

PRIMARY outcome

Timeframe: 6-weeks

Measurement of impairment, minimum value 0, maximum value 66, higher score means a better outcome. Subscales are summed.

Outcome measures

Outcome measures
Measure
Vagus Nerve Stimulation (VNS) + Rehabilitation (1)
n=8 Participants
This group receives vagus nerve stimulation during rehabilitation. VNS and rehabilitation are the interventions. Vagus Nerve Stimulation (VNS)
Vagus Nerve Stim (VNS) + Rehabilitation (2) - Comparator
n=9 Participants
This group receives rehabilitation and VNS, but the VNS is different than given in the other group (rehabilitation is the only true intervention in this group). It may not be as effective as the other group's settings. Both groups receive the same amount of rehabilitation. Vagus Nerve Stimulation (VNS)
Change in Upper Extremity Fugl-Meyer (UEFM)
7.6 units on a scale
Standard Deviation 4.8
5.3 units on a scale
Standard Deviation 3.2

SECONDARY outcome

Timeframe: 6-weeks

Measurement of upper limb function/mobility. For Functional Assessment - minimum is 0 and maximum is 3. A higher score means a better outcome.

Outcome measures

Outcome measures
Measure
Vagus Nerve Stimulation (VNS) + Rehabilitation (1)
n=8 Participants
This group receives vagus nerve stimulation during rehabilitation. VNS and rehabilitation are the interventions. Vagus Nerve Stimulation (VNS)
Vagus Nerve Stim (VNS) + Rehabilitation (2) - Comparator
n=9 Participants
This group receives rehabilitation and VNS, but the VNS is different than given in the other group (rehabilitation is the only true intervention in this group). It may not be as effective as the other group's settings. Both groups receive the same amount of rehabilitation. Vagus Nerve Stimulation (VNS)
Change in Wolf Motor Function Test Functional Assessment (WMFT)
0.25 units on a scale
Standard Deviation 0.24
.13 units on a scale
Standard Deviation .17

Adverse Events

Vagus Nerve Stimulation (VNS) + Rehabilitation (1)

Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths

Vagus Nerve Stim (VNS) + Rehabilitation (2) - Comparator

Serious events: 3 serious events
Other events: 4 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Vagus Nerve Stimulation (VNS) + Rehabilitation (1)
n=8 participants at risk
This group receives vagus nerve stimulation during rehabilitation. VNS and rehabilitation are the interventions. Vagus Nerve Stimulation (VNS)
Vagus Nerve Stim (VNS) + Rehabilitation (2) - Comparator
n=9 participants at risk
This group receives rehabilitation and VNS, but the VNS is different than given in the other group (rehabilitation is the only true intervention in this group). It may not be as effective as the other group's settings. Both groups receive the same amount of rehabilitation. Vagus Nerve Stimulation (VNS)
Infections and infestations
Wound Infection
0.00%
0/8
11.1%
1/9 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Shortness of Breath and Dysphagia
0.00%
0/8
11.1%
1/9 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Hoarseness
0.00%
0/8
11.1%
1/9 • Number of events 1

Other adverse events

Other adverse events
Measure
Vagus Nerve Stimulation (VNS) + Rehabilitation (1)
n=8 participants at risk
This group receives vagus nerve stimulation during rehabilitation. VNS and rehabilitation are the interventions. Vagus Nerve Stimulation (VNS)
Vagus Nerve Stim (VNS) + Rehabilitation (2) - Comparator
n=9 participants at risk
This group receives rehabilitation and VNS, but the VNS is different than given in the other group (rehabilitation is the only true intervention in this group). It may not be as effective as the other group's settings. Both groups receive the same amount of rehabilitation. Vagus Nerve Stimulation (VNS)
Musculoskeletal and connective tissue disorders
Pain/Bruising from implant surgery
50.0%
4/8 • Number of events 4
44.4%
4/9 • Number of events 4

Additional Information

VP Clinical Affairs

MicroTransponder Inc.

Phone: 5123714160

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place